✦ LIBER ✦

R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma

✍ Scribed by Yuko Mishima, Yasuhito Terui, Masahiro Yokoyama…

Book ID: 120800828
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 171 KB
Volume: 1
Category: Article
ISSN: 2162-3619
DOI: 10.1186/2162-3619-1-30

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Limited-Stage Diffuse Large B-cell Lymph

Limited-Stage Diffuse Large B-cell Lymphoma in Head and Neck Treated With CHOP or Rituximab-CHOP (R-CHOP) Plus Radiation Therapy

✍ Ohga, S.; Nakamura, K.; Shioyama, Y.; Sasaki, T.; Nonoshita, T.; Yoshitake, T.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Impact of relative dose intensity (RDI)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

✍ Yoshiki Terada, Hirohisa Nakamae, Ran Aimoto… 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 426 KB

Cost-Effectiveness Analysis of the Addit

Cost-Effectiveness Analysis of the Addition of Rituximab to CHOP in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma

✍ Felicetto Ferrara, Dr Roberto Ravasio 📂 Article 📅 2008 🏛 Springer International Publishing AG 🌐 English ⚖ 124 KB

Indoleamine 2,3-dioxygenase in tumor tis

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

✍ Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Masato Hoshi; Nobuhiro Kanemur 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 352 KB

P138 Change in prognosis due to differen

P138 Change in prognosis due to differences in cellular origin of diffuse large B-cell lymphoma in response to R-CHOP therapy

✍ T. Schneider; E. Tóth; A. Matolcsy; Zs. Molnár; B. Deák; E. Várady; M. Lakos; A. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB

We have compared two different solubilization buffers, we also evaluated protein precipitation with ethanol (EtOH) and optimized 2-DE conditions for human myeloma proteins. Myeloma cell line ARH-77 was used to in the pilot study. Proteins from myeloma cell line ARH-77 were separated by 2-DE using a

Pegfilgrastim as hematopoietic support f

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma

✍ Ulrich J. M. Mey; Anna Maier; Ingo G. H. Schmidt-Wolf; Carsten Ziske; Helmut For 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 136 KB